Kaposi’s sarcoma-associated herpesvirus at 27

Marta Maria Gaglia

Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, 02111, USA

A R T I C L E   I N F O

Keywords:
KSHV
HHV-8
Kaposi’s sarcoma
PEL
Viral oncogenesis

A B S T R A C T

Kaposi’s sarcoma-associated herpesvirus (KSHV) was discovered 27 years ago and its link to several pathologies – Kaposi’s sarcoma, primary effusion lymphoma, and the B cell variant of Multicentric Castleman disease – is now well established. However, many questions remain about how KSHV causes tumors. Here, I will review studies from the last few years (primarily 2019–2021) that report new information about KSHV biology and tumorigenesis, including new results about KSHV proteins implicated in tumorigenesis, genetic and environmental variability in KSHV-related tumor development, and potential vulnerabilities of KSHV-caused tumors that could be novel therapeutic targets.

1. Introduction

The gamma-herpesvirus Kaposi’s sarcoma-associated herpesvirus (KSHV) was discovered 27 years ago in a Kaposi’s sarcoma (KS) lesion of an AIDS patient [1]. Since then, the connection between infections with KSHV and the tumors it causes – KS and primary effusion lymphoma (PEL) – has become the best established among the human tumor viruses. KSHV is found in all KS and PEL samples. KS is a tumor of endothelial cells that is characterized by highly vascularized lesions on the skin and mucosal tissue, with varying degree of aggressive presentations. PEL is a rare but highly fatal B-cell lymphoma that is usually found in body cavities and is composed of plasmablastic cells. In addition to KS and PEL, KSHV also causes the B cell variant of Multicentric Castleman Disease, a lymphoproliferative disease, and an inflammatory syndrome termed KSHV-induced cytokine syndrome (KICS). KSHV-induced diseases are predominantly found in immunocompromised individuals. AIDS-associated KS (also known as epidemic KS) and iatrogenic KS arise as a consequence of immunosuppression from AIDS or immunosuppressant therapy after transplants, respectively. However, there are subtypes of KS that appear to occur in the absence of overt immunosuppression, such as the classical KS that occurs predominantly in older men of Mediterranean descent, and the endemic KS that is common in African adults and children. Because of the association with immunosuppression, KS became very prominent during the AIDS epidemic, which led to the discovery of KSHV. Since the advent of anti-retroviral therapy (ART), cases of KS in the US have drastically decreased. However, in the past 10 years they have leveled to ~900 cases a year [2]. KS remains the second most common AIDS-associated cancer in the US and the second most common cancer in sub-Saharan Africa. For reasons that remain unclear, ART has also been less successful in reducing KS incidence in sub-Saharan Africa, possibly because more patients in this region tend to start therapy when they have already developed advanced KS [3]. To date, approved therapies for KS and PEL treatment remain very limited and have limited efficacy. KS is mostly managed by counteracting the immune suppression, while PEL and MCD prognosis remains very poor, with patients typically surviving for only a few months to a year. However, since it is discovery in 1994, we have learned a lot about the biology and pathogenesis of KSHV and its interaction with the infected host, which will hopefully lead to new avenues to therapy. In this review, I will cover advances on some major questions in the KSHV field, focusing particularly on studies from the last few years.

2. How does KSHV infection lead to tumorigenesis?

Although the epidemiological connection between KSHV and KS, PEL, and MCD is well-established, the process of KSHV-induced transformation is still poorly understood. Like all herpesviruses, KSHV can infect cells in a lytic or latent fashion (Fig. 1). Many of the KS and PEL tumor cells are latently infected, although lytic replication is prominent in MCD. During latent infection, only a few viral genes are expressed: latent nuclear antigen (LANA/ORF73), viral cyclin (vCyclin/ORF72), viral FLIP (vFLIP/K13), the Kaposins (K12), 12 viral micro RNAs (K-miRNAs) and, in PEL cells, viral interferon regulatory factor 3 (vIRF3/K10.5/LANA2). LANA in particular is key for maintenance of latent infection, because it tethers the viral genome to the host chromosomes.

E-mail address: Marta.Gaglia@tufts.edu.

https://doi.org/10.1016/j.tvr.2021.200223
Received 2 April 2021; Received in revised form 16 June 2021; Accepted 17 June 2021
Available online 19 June 2021
2666-6790/© 2021 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
preventing virus loss during cell division [4]. While the role of LANA in KSHV latency has been well established for many years, recently there have been increasing efforts to target LANA for therapy, with the idea of reducing viral persistence. Two studies have shown that in an experimental setting, CRISPR-Cas9 could be used to damage the LANA gene and thus reduce latent virus carriage [5,6]. Other groups have sought to identify small molecules that interfere with LANA-DNA interactions [7, 8]. However, these approaches are still at an early experimental stage, and no in vivo studies have been performed. Therefore, it is unclear whether they can be adapted for therapy and whether there would be a significant impact on tumorigenesis in vivo. Studies over the last 27 years have also uncovered roles for LANA, the other latent proteins, and the K-miRNAs in cell survival, proliferation and/or angiogenesis. These activities likely contribute to tumorigenesis. Nonetheless, new aspects of the function of these proteins and RNAs continue to be reported. For example, in the last couple of years LANA has been shown to drive cleavage of the Aurora B kinase [9]. LANA also increases expression of the pro-survival factor MCL-1 by sequestering the E3 ubiquitin ligase FBW7, which normally drives MCL-1 degradation [10]. vCyclin was recently shown to help KSHV-infected primary lymphatic endothelial cells overcome senescence, a growth arrest that functions as anti-oncogenic mechanism [11]. LANA may also be able to overcome cell senescence by activating an alternative pathway of telomere maintenance through homologous recombination, since telomere shortening leads to senescence [12]. Whether a specific KSHV factor is important in telomere maintenance by homologous recombination remains unknown. The function of viral K-miRNAs and other non-coding RNAs in tumorigenesis was recently reviewed by Tagawa et al. [13], therefore I will not discuss it more in detail here.

One theme that has consistently emerged from studies over the last 27 years is that, despite the pro-oncogenic functions of latent genes, simply infecting cells with KSHV does not transform them, unlike infection with the related gammaherpesvirus Epstein-Barr virus (EBV). For example, whereas vCyclin can propel cells past senescence, the infected cells still undergo crisis, a second proliferative block during which the cells cease to grow and die [11]. Paradoxically, transformation has been seen more often with single KSHV gene expression or in cell types that are not considered relevant for human tumors. For example, overexpression of the viral protein kinase vPK/ORF36 alone induces lymphomas in aged mice [14]. Also, rat mesenchymal precursor cells become transformed after KSHV infection and can give rise to tumors in nude mice [15]. Consistent with the poor transforming potential of KSHV, substantial evidence points to a heavy involvement of paracrine signaling in the development and maintenance of KS, PEL and MCD. In particular, cytokines like interleukin 6 (IL-6) and angiogenic factors like vascular endothelial growth (VEGF) have been implicated in KSHV-dependent tumorigenesis and are in some cases produced by KSHV lytically infected cells (see section 3) (Fig. 1). New potential therapies based on altering cytokine signaling are being explored for these diseases, as recently reviewed in Alomari and Totonchy [16]. VEGF-A targeting antibodies have also shown some promise in in vivo models, especially antibody fragments that may have better penetration in tumors [17]. Yet an additional wrinkle to the role of inter-cellular communication in tumorigenesis was added by the discovery that extracellular vesicles released from KSHV-infected cells may also alter the phenotype of nearby uninfected cells [18] (Fig. 1). In general, tumorigenesis by KSHV appears to rely on a complex set of interactions between infected cells and the microenvironment that we are still in the process of deciphering.

3. What is the contribution of lytic replication to tumorigenesis?

Another key component of the tumorigenesis process is viral lytic replication. This is at first glance surprising, as replicating cells are expected to die and thus cannot directly contribute to tumor mass. The contribution of lytic replication to tumorigenesis was initially revealed in the late 90s by the unexpected regression of Kaposi’s sarcoma in AIDS patients under treatment with anti-herpesviral drugs for CMV retinitis [19]. New findings over the years have provided additional support for this model. For example, recent longitudinal studies have
shown that antibodies against lytic proteins can be detected in patients that develop Kaposi’s sarcoma prior to the onset of disease [20]. The presence of these antibodies suggests that high levels of reactivation from latency occurred before disease development.

Lytic replication is thought to support tumorgenesis in several ways. First of all, the KSHV genome is routinely lost during passage of KSHV-infected cells, including endothelial cells (although it is retained in cell lines derived from PEL tumors). Therefore, in vivo lytic reactivation and virus production is needed to maintain the population of latently infected cells (Fig. 1). Interestingly, evidence from studies using 3D tissue culture models indicate that in a tissue there is either more spontaneous lytic reactivation and/or more efficient reinfection of cells, which enables better genome maintenance relative to cells grown in 2D culture [21,22]. In addition to reseeding the latent population, lytic genes may also serve oncogenic functions, in some cases because they promote pro-tumorigenic and angiogenic paracrine signaling (Fig. 1). Viral IL-6 homolog (vIL-6/K2), viral G-protein coupled receptor (vGPCR/ORF74), viral interferon regulatory factor 1 (vIRF1/K9), viral protein kinase (vPK/ORF36), and the membrane proteins K1 and K15 are all genes that are classically considered lytic but have oncogenic functions. vIL-6 is a homolog of the human cytokine and binds the gene expression in tumors. Expression profiling of KS lesions suggested that lytic reactivation may vary substantially between patients and/or lesions, although some expression of genes classically considered to be lytic is found in most lesions [37,38]. Sequencing of the lymphoma cell line BCP-1 showed high expression of a subset of lytic genes, including PAN and a cluster of genes involved in immune regulation (K2, K4, K5) [39]. Single-cell RNA sequencing of the BC1 PEL line also detected many lytic genes in up to 50% of the cells, but at very low levels per cell [40].

In any case, there is considerable interest in understanding whether lytic replication or its effects can be targeted for therapy. This has also coincided with the development of new reagents that have improved our ability to study the lytic cycle and generate KSHV mutants. These reagents include systems in which reactivation of the lytic cycle can be induced more efficiently through doxycycline-inducible exogenous expression of the KSHV master lytic regulator, RTA/ORF50 [41-43]. Moreover, bacterial artificial chromosome-based systems have been developed to generate KSHV mutants, in particular the now widely used BAC16 system [44,45].

4. What is the origin of the KS spindle cells?

Another unresolved question is the origin of the cells that are infected by KSHV and give rise to KS. The long-standing model is that the most likely targets are endothelial cells, since KS cells express both panendothelial and lymphatic endothelial markers [46]. However, KS cells also appear poorly differentiated and express markers of other cell types. Indeed, KSHV infection causes reprogramming of the cellular gene expression, as well as a morphological change of the cells to KS “spindle cells” [47,48] (Fig. 1). In 2004, several studies showed that KSHV can infect both blood and lymphatic endothelial cells, and alter gene expression in both cell types to an intermediate state between the two [49-51]. Since then, it has become apparent that lymphatic endothelial cells can support spontaneous reactivation by KSHV, which is thought to be important for tumorgenesis (see section 3) and maintenance of the latent cell pool (Fig. 1). Two recent studies have revealed that this is because these cells express the PROX1 transcription factor, which is a key protein for lymphatic endothelium development [34,52]. PROX1 directly stimulates expression of RTA/ORF50, the master regulator of lytic reactivation, by binding to its promoter [34,52]. Gramellotti et al. also showed a role for another lymphatic endothelium transcription factor, SOX18, in KSHV persistence [34]. SOX18 promotes an increase in the number of latent genomes by binding near the origin of replication [34]. Interestingly, whereas PROX1 and SOX18 regulate each other during lymphatic endothelium development, KSHV decouples this reciprocal regulation, presumably to facilitate the continued expression of both transcription factors [34]. Since KSHV infection also induces higher levels of PROX1 and SOX18 expression in blood endothelial cells [34], these results suggest that KSHV infection drives cells to return to an embryonic stage of lymphatic endothelial development, when PROX1 and SOX18 are highly expressed. The two studies on PROX1 also suggest that the spontaneous reactivation in lymphatic endothelial cells is key to maintaining and expanding the population of infected cells in the tumor [34,52].

Notwithstanding these results in endothelial cells, some groups have advanced the idea that mesenchymal stem cells may be the source, or at least one of the sources, of the KS spindle cells [53-56]. Indeed, KS spindle cells also express mesenchymal markers like nestin or PDGFRA [54]. Some studies have suggested that this could be due to an endothelial-to-mesenchymal (EndMT) transition that occurs in response to KSHV infection of endothelial cells [21,54-59] (Fig. 2). EndMT is a transdifferentiation process similar to epithelial-to-mesenchymal transition (EMT), which is implicated in tumorgenesis and metastasis [60,61]. EndMT may be related to LANA’s ability to turn on expression of mesenchymal markers [62]. However, several studies over the years have shown that KSHV can also latently infect both rodent and human mesenchymal precursor/stem cells in cell culture [15,53-58]. KSHV-infected mesenchymal stem cells express a mixed set of
KSHV KSHV
lymphatic
endothelial cells
mesenchymal
cell stem
cells
EndMT
MEndT
spindle cells
paracrine
signals
uparrow
motility, growth,
angiogenesis
tumor formation
4

Fig. 2. Potential origins of spindle cells from endothelial and mesenchymal cells. KSHV infection may lead to de-differentiation of both endothelial and mesenchymal cells through endothelial-to-mesenchymal (EndMT) and mesenchymal-to-endothelial transition (MEndT), respectively. The infected cells thus become more motile, angiogenic and proliferative. Nonetheless, paracrine signals are likely needed for full transformation of the cells.

Figure 2: Potential origins of spindle cells from endothelial and mesenchymal cells. KSHV infection may lead to de-differentiation of both endothelial and mesenchymal cells through endothelial-to-mesenchymal (EndMT) and mesenchymal-to-endothelial transition (MEndT), respectively. The infected cells thus become more motile, angiogenic and proliferative. Nonetheless, paracrine signals are likely needed for full transformation of the cells.

While KSHV is required for KS and PEL tumorigenesis, it is clearly not sufficient. There is a lot of individual variability in disease development and presentation within both AIDS-associated KS and endemic KS. Several studies have tried to decipher factors that underlie this disease variability, as well as the variability in KSHV prevalence among different populations. For example, KSHV seropositivity is very high in Africa but low in North America [68]. Although one model has been that the risk of KS development may depend on the strength of the immune response of different individuals, recent studies have argued against this idea. For example, KS patients do not have lower levels of anti-KSHV neutralizing antibodies or antibodies mediating antibody-dependent cellular cytotoxicity relative to disease-free KSHV seropositive individuals [69,70]. Moreover, T cell responses are similarly weak in both groups [71]. Another possibility is that there are genetic differences between populations that underlie differences in risk. This is an attractive model since there is clear familial clustering of KS cases (for example [72]). Thus far, targeted studies or studies of early-onset KS cases have predominantly been used to identify genetic determinants of KSHV susceptibility or KS and MCD development. These studies have identified several interesting candidate polymorphisms, reviewed more extensively Blumenthal et al. [73]. In particular, polymorphism in specific HLA subtypes, in genes involved in regulation of immune responses like NFκB, TRIM31, LY6G6C, and in subtypes of the natural killer cell receptor KIR have been found to be associated with KSHV infection or development of KS or MCD [73]. A genetic association with both susceptibility to infection and disease development was also found for Ephrin A, a potential entry receptor for KSHV [73,74]. However, most of these associations were found in a single study and their wider importance as genetic determinants of KSHV infection and disease remains uncertain.
develops in cells that are both KSHV and EBV positive, Faure et al. [78] reviewed by Thakker and Verma [77]. In particular, since PEL often influental factor for disease progression may be co-infections (recently set up a system of dual infection in primary peripheral B cells, and found that EBV infection shortly after KSHV infection promoted transformation of the B cells and higher KSHV infection. This reinforces that idea that dual KSHV/EBV infection is key for tumorigenesis in most cases of PEL. Lastly, the possibility that specific mutations need to arise in KSHV genomes to promote tumorigenesis has been considered. To test this hypothesis, a recent study sequenced several KSHV isolates from both oral swabs and tumors of patients [79]. While they found very few little intra-host variability at single nucleotide level, consistent with the proof-reading activity of both the host and viral DNA polymerases, they did see that in several of the tumors the KSHV genome had major rearrangements with translocations and duplications [79]. However, it is unclear if these rearrangements contributed to tumorigenesis or were simply a consequence of genomic instability in the tumor tissue. Altogether, it is clear that multiple factors including viral genetics, host genetics and environmental factors contribute to the development of KS and PEL tumors.

6. What host activities are KSHV tumors addicted to that could be used as therapeutic targets?

Many tumors are “addicted” to specific cellular pathways and oncogenes, and these addictions represent potential vulnerabilities and drug targets for therapy [80]. While over the years many targeted studies have uncovered roles of individual pathways in KS and KSHV biology, with the advent of CRISPR screening it has become possible to comprehensively interrogate the landscape of genes and pathways necessary for KSHV tumorigenesis [81]. Three recent studies have sought to use genome-wide CRISPR screens to identify pathways that KSHV-induced tumors are “addicted” to. These screens looked for genes required for cell survival and growth in three different KSHV latent infection systems. Manzano et al. used BCBL1 cells originally derived from a PEL patient [82], Holmes et al. employed a widely used system of KSHV-infected human endothelial cells [83], and Gruffaz et al. used KSHV-infected rat embryonic mesenchymal stem cells [84]. Manzano et al. [82] found 210 genes that are specifically required for PEL growth and presumably oncogenesis, including the apoptosis regulators MCL1 and cFLIP, and the cyclin CCND2. cFLIP and CCND2 were unexpected, as the virus encodes homologs of these proteins (vFLIP and vCyclin). MCL1 and CCND2 were particularly interesting because they can be targeted with existing drugs. Indeed, treatment of multiple PEL cell lines with the MCL1 inhibitor 63845 or the CCND2 inhibitor palbociclib led to cell death or cell cycle arrest, respectively [82]. Another key regulator of PEL growth identified in this study was IRF4, which, together with its cofactor BATF and KSHV vIRF3, binds “super-enhancer” sequences [85]. These super-enhancers in turn regulate many of the key genes that PEL cells require for growth, including MCL1, cMYC and IRF4 itself [86]. The importance of super-enhancers for PEL growth explains why PEL are sensitive to BET domain inhibitors, as BET domain-containing proteins bind super-enhancers [87]. Holmes et al. [83] identified mitochondrial translation as essential for the growth of KSHV-infected endothelial cells. They also found that mitochondrial size and numbers were altered by KSHV latent infection in these cells [83]. Moreover, treatment with antibiotics that affect mitochondrial translation, such as chloramphenicol and tigecycline, reduced the growth of KSHV-infected endothelial cells and triggered cell death in PEL cell lines, pointing to these molecules as potential new anti-KSHV agents [83]. Gruffaz et al. [84] found a requirement for the nuclear export machinery for proliferation and growth in soft agar of KSHV-transformed rat embryonic mesenchymal stem cells. Pharmacological inhibition of the export protein XPO1 by KPT-8602 led to growth inhibition, which was likely due to activation of p53 [84]. Although these studies have focused on different vulnerabilities, they did find a few shared genes. For example, the screen hits from Manzano et al. [82] also include several subunits of the mitochondrial ribosome, like the ones identified in the Holmes et al. [83] study. Of note, these studies have revealed interesting new potential targets for treatment. However, these potential treatments have so far only been tested in tissue culture and more research is needed to determine whether they can truly be used for therapy.

Another aspect of cellular physiology that could constitute a therapeutic target is cellular metabolism. Cellular metabolism is often remodeled in cancers, with increased dependency on aerobic glycolysis and glutamine metabolism for growth, also known as the Warburg effect [88]. Since 2010, it has been apparent that latent KSHV infection changes many aspects of metabolism in a way that is similar to the Warburg effect. KSHV infection increases the cell’s reliance on glycolysis and glutaminolysis and upregulates fatty acid metabolism and peroxisome number (reviewed in Lagunoff [89] and Dai et al. [90]). However, there has been some controversy surrounding these ideas, because some of the results differ between the latently infected endothelial cell model and the rat mesenchymal transformation model. In the KSHV-transformed rat mesenchymal precursor cells, glycolysis is not required for growth and glutaminolysis provides nucleotides for DNA replication rather than energy [91,92]. It remains to be seen whether the transformed phenotype or the difference in the source of the cells explains this discrepancy. RNAseq data from KS tumor lesions present yet another picture. Gene expression changes detected in the KS samples also suggest a shift towards glycolysis, but instead point to a decrease in lipid metabolism [38]. Again, it is unclear if the discrepancy between these results and the studies in KS are due simply to the system. It is also possible that lipid metabolism is reduced in these KS samples because they are from HIV-positive patients undergoing ART, which could also affect lipid metabolism [38]. An additional KSHV-associated change that is also commonly found in cancer cells is increased proline metabolism [93]. Mediated by the K1 protein, this metabolic change is required for high levels of proliferation of KSHV-infected cells in 3D culture [93]. In principle, many of the KSHV-associated metabolic changes could be exploited for targeted therapy, although at present the details remain to be worked out.

In addition to these pathways, it is possible that many genes involved in processes such as control of lytic gene expression and endothelial cell infection, including those described in other sections of this review, may serve as targets for KSHV treatment. For example, as mentioned in section 4, Gramolielli et al. reported that SOX18, an endothelial transcription factor, is important for genome maintenance during latent infection. The authors also showed that disrupting SOX18 dimerization and function with the small molecules SM4 or R-(+-)propanolol reduces genome copies in latently-infected cells [34], suggesting these treatments could be used as a therapeutic strategy against KS and KSHV infections. This and other findings described in this section exemplify how basic studies on the biology of KSHV during latent and lytic infection may inform novel treatment strategies.

7. Conclusions

27 years after its discovery, we have made progress on understanding
the biology and tumorigenesis of KSHV, but many questions remain partly unresolved. In the last ten years, the range of tools to study KSHV has been expanded thanks to the work of multiple laboratories, which has allowed us to better dissect the function of proteins and to study the lytic cycle more in depth. However, we still lack a good transformation model that recapitulates K5 or PEL development in human cells, and an animal model to study the interactions between the tumors and the physiology of the host organism. Nonetheless, many of the advances in the basic understanding of KSHV biology and its role in tumorigenesis provide hope that better treatments will be coming in the near future.

Author statement
Marta Maria Gaglia: Funding; Writing – original draft.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

I apologize for not referencing all relevant studies because of length limitations. I thank Rachel Lent for critical reading of the manuscript. Work on KSHV in the Gaglia laboratory is supported by American Cancer Society Research Scholar Grant 131320-RSG-17-191-01-MPC.

References

[1] Y. Chang, E. Cesarman, M.S. Pesin, F. Lee, J. Culpepper, D.M. Knowles, et al., Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposis's sarcoma. Science 266 (5192) (1994 Dec 16) 1805-1809.
[2] H.A. Robbins, R.M. Pfeiffer, M.S. Shiels, J. Li, H.I. Hall, E.A. Engels, Excess Cancers among HIV-Infected People in the United States, NCIJ Cancer Inst [Internet] 107 (4) (2015 Apr 1), https://doi.org/10.1093/jnci/dju503 [cited 2021 Mar 21].
[3] O. Ngalamika, S. Munsaka, S.J. Lidenge, J.T. West, C. Wood, Antiretroviral drugs as a cause of Kaposi's sarcoma: a systematic review and meta-analysis. J. Intern Med. 282 (5) (2017 Sep) 476-486.
[4] L. Wang, D.P. Dittmer, C.C. Tomlinson, F.D. Fakhari, B. Damania, Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells, J. Mol. Med. 99 (3) (2021 Mar) 425-438.
[5] S. Sakakibara, G. Tosato, Viral interleukin-6 role in Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies, J. Interferon Cytokine Res. 31 (11) (2011 Jul 18) 791-801.
[6] R. Rivera-Soto, N.J. Dissinger, B. Damania, Kaposi's sarcoma-associated herpesvirus viral interleukin-6 signaling upregulates integrin β3 levels and is dependent on STAT3, J Virol [Internet] 94 (5) (2020 Apr 1) e01384-019 [cited 2021 Mar 29]; Available from: https://jvi.asm.org/content/94/5/e01384-19.
[7] W. Li, Q. Wang, X. Qi, Y. Guo, H. Lu, Y. Chen, et al., Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1, Oncogene 39 (23) (2020 Jun) 4603-4618.
[8] B. Abere, T.F. Schulz, KSHV non-structural membrane proteins involved in the activation of intracellular signaling pathways and the pathogenesis of Kaposi's sarcoma, Curr Opin Virol 16 (2016 Oct 1) 11-19.
[9] L.E. Cavallin, Q. Ma, J. Naipauer, S. Gupta, M. Kuriain, P. Locatelli, et al., KSHV-induced ligand mediated activation of PDGF receptor-alpha drives Kaposi's sarcoma. PLoS Pathog. 14 (7) (2018 Jul 9), e0017755.
[10] M.V. Medina, A. D’Agostino, Q. Ma, P. Eroles, L. Cavallin, C. Chiozzini, et al., KSHV G protein-coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi’s sarcoma, PLoS Pathog. 16 (10) (2020 Oct 15), e1009096.
[11] J. Bhatt, J.P. Wong, M.S. Weinberg, K.M. Host, L.C. Giffin, J. Buijnink, et al., A viral kinase mimics Smk6 kinase to enhance cell proliferation, Proc. Natl. Acad. Sci. Unit. States Am. 113 (28) (2016 Jul 12) 7876-7881.
[12] T. Li, S.R. Jacobs, J.A. West, C. Stopford, Z. Zhang, S. Davis, et al., Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses, Proc. Natl. Acad. Sci. U. S. A. 112 (31) (2015 Aug 4) E4306-E4315.
[13] W. Li, Q. Wang, X. Qi, H. Lu, Y. Chen, J. Shi, et al., An oncogenic viral interferon regulatory factor dysregulates expression of MCL-1 by targeting FBW7, PLoS Pathog. 17 (1) (2021 Jan 20), e1009179.
[14] T. Dubich, A. Dittrich, K. Bouzet, R. Geffers, G. Bücke, M. Koster, et al., 3D culture conditions support Kaposi’s sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells, J. Mol. Med. 99 (3) (2021 Mar) 425-438.
[15] S. Cao, M.J. Strong, X. Wang, W.N. Moss, M. Concha, Z. Lin, et al., High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the cancer cell line encyclopedia project, J. Virol. 89 (1) (2015 Jan 1) 713-729.
M.M. Gaglia

[40] N.C. Rondeau, M.O. Finlayson, J.L. Miranda, Widespread traces of lytic Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma at single-cell resolution, Available from: Front Cell Microbiol [Internet] 11 (2021) 375 (2020 Nov 5) e00851-20 [cited 2021 Mar 21], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940174/

[41] H. Nakamura, M. Lu, Y. Gwack, J. Souvlis, S.L. Zeichner, J.U. Jung, Global changes in Kaposi’s sarcoma-associated herpesvirus gene expression during reactivation of a tetracycline-inducible Rta transactivator, J. Virol. 77 (7) (2003 Apr) 4205–4220.

[42] J. Myoung, D. Ganem, Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction, J. Virol. Methods 174 (1-2) (2011 Jun 12–21).

[43] S.J. Dollery, T.D. Maldonado, E.A. Brenn, E.A. Berger, ITIME:219—an immobilized KSHV IE promoter in a bacterial artificial chromosome clone to stimulate from latency to lytic replication and infectious virus release, Available from: Front Cell Infect Microbiol [Internet] 11 (2021) 264 [cited 2021 May 16], http://www.frontiersin.org/articles/10.3389/fcimb.2021.654396/full.

[44] N.C. Rondeau, M.O. Finlayson, J.L. Miranda, Widespread traces of lytic Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma at single-cell resolution, Available from: Front Cell Microbiol [Internet] 11 (2021) 375 (2020 Nov 5) e00851-20 [cited 2021 Mar 21], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940174/.

[45] R. Shohan, N. Labo, M. Trivett, W. Miley, V. Marshall, L. Coren, et al., T-cell responses to KS infection: a systematic approach, Oncotarget 8 (65) (2017 Nov 25) 109402–109416.

[46] H. Nakamura, M. Lu, Y. Gwack, J. Souvlis, S.L. Zeichner, J.U. Jung, Global changes in Kaposi’s sarcoma-associated herpesvirus gene expression during reactivation of a tetracycline-inducible Rta transactivator, J. Virol. 77 (7) (2003 Apr) 4205–4220.

[47] J. Myoung, D. Ganem, Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction, J. Virol. Methods 174 (1-2) (2011 Jun 12–21).

[48] S.J. Dollery, T.D. Maldonado, E.A. Brenn, E.A. Berger, ITIME:219—an immobilized KSHV IE promoter in a bacterial artificial chromosome clone to stimulate from latency to lytic replication and infectious virus release, Available from: Front Cell Infect Microbiol [Internet] 11 (2021) 264 [cited 2021 May 16], http://www.frontiersin.org/articles/10.3389/fcimb.2021.654396/full.

[49] N.C. Rondeau, M.O. Finlayson, J.L. Miranda, Widespread traces of lytic Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma at single-cell resolution, Available from: Front Cell Microbiol [Internet] 11 (2021) 375 (2020 Nov 5) e00851-20 [cited 2021 Mar 21], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940174/.

[50] R. Shohan, N. Labo, M. Trivett, W. Miley, V. Marshall, L. Coren, et al., T-cell responses to KS infection: a systematic approach, Oncotarget 8 (65) (2017 Nov 25) 109402–109416.

[51] H. Nakamura, M. Lu, Y. Gwack, J. Souvlis, S.L. Zeichner, J.U. Jung, Global changes in Kaposi’s sarcoma-associated herpesvirus gene expression during reactivation of a tetracycline-inducible Rta transactivator, J. Virol. 77 (7) (2003 Apr) 4205–4220.

[52] J. Myoung, D. Ganem, Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction, J. Virol. Methods 174 (1-2) (2011 Jun 12–21).

[53] S.J. Dollery, T.D. Maldonado, E.A. Brenn, E.A. Berger, ITIME:219—an immobilized KSHV IE promoter in a bacterial artificial chromosome clone to stimulate from latency to lytic replication and infectious virus release, Available from: Front Cell Infect Microbiol [Internet] 11 (2021) 264 [cited 2021 May 16], http://www.frontiersin.org/articles/10.3389/fcimb.2021.654396/full.

[54] N.C. Rondeau, M.O. Finlayson, J.L. Miranda, Widespread traces of lytic Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma at single-cell resolution, Available from: Front Cell Microbiol [Internet] 11 (2021) 375 (2020 Nov 5) e00851-20 [cited 2021 Mar 21], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940174/.

[55] R. Shohan, N. Labo, M. Trivett, W. Miley, V. Marshall, L. Coren, et al., T-cell responses to KS infection: a systematic approach, Oncotarget 8 (65) (2017 Nov 25) 109402–109416.

[56] H. Nakamura, M. Lu, Y. Gwack, J. Souvlis, S.L. Zeichner, J.U. Jung, Global changes in Kaposi’s sarcoma-associated herpesvirus gene expression during reactivation of a tetracycline-inducible Rta transactivator, J. Virol. 77 (7) (2003 Apr) 4205–4220.

[57] J. Myoung, D. Ganem, Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction, J. Virol. Methods 174 (1-2) (2011 Jun 12–21).

[58] S.J. Dollery, T.D. Maldonado, E.A. Brenn, E.A. Berger, ITIME:219—an immobilized KSHV IE promoter in a bacterial artificial chromosome clone to stimulate from latency to lytic replication and infectious virus release, Available from: Front Cell Infect Microbiol [Internet] 11 (2021) 264 [cited 2021 May 16], http://www.frontiersin.org/articles/10.3389/fcimb.2021.654396/full.

[59] N.C. Rondeau, M.O. Finlayson, J.L. Miranda, Widespread traces of lytic Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma at single-cell resolution, Available from: Front Cell Microbiol [Internet] 11 (2021) 375 (2020 Nov 5) e00851-20 [cited 2021 Mar 21], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940174/.

[60] R. Shohan, N. Labo, M. Trivett, W. Miley, V. Marshall, L. Coren, et al., T-cell responses to KS infection: a systematic approach, Oncotarget 8 (65) (2017 Nov 25) 109402–109416.

[61] H. Nakamura, M. Lu, Y. Gwack, J. Souvlis, S.L. Zeichner, J.U. Jung, Global changes in Kaposi’s sarcoma-associated herpesvirus gene expression during reactivation of a tetracycline-inducible Rta transactivator, J. Virol. 77 (7) (2003 Apr) 4205–4220.

[62] J. Myoung, D. Ganem, Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction, J. Virol. Methods 174 (1-2) (2011 Jun 12–21).

[63] S.J. Dollery, T.D. Maldonado, E.A. Brenn, E.A. Berger, ITIME:219—an immobilized KSHV IE promoter in a bacterial artificial chromosome clone to stimulate from latency to lytic replication and infectious virus release, Available from: Front Cell Infect Microbiol [Internet] 11 (2021) 264 [cited 2021 May 16], http://www.frontiersin.org/articles/10.3389/fcimb.2021.654396/full.

[64] N.C. Rondeau, M.O. Finlayson, J.L. Miranda, Widespread traces of lytic Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma at single-cell resolution, Available from: Front Cell Microbiol [Internet] 11 (2021) 375 (2020 Nov 5) e00851-20 [cited 2021 Mar 21], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940174/.
oncogenic virus, Available from: mBio [Internet] 8 (4) (2017 Sep 6) e01179-17 [cited 2021 Mar 30], https://mbio.asm.org/content/8/4/e01179-17.

[92] Y. Zhu, S.R. da Silva, M. He, Q. Liang, C. Lu, P. Peng, et al., An oncogenic virus promotes cell survival and cellular transformation by suppressing glycolysis, PLoS Pathog. 12 (5) (2016 May 17), e1005648.

[93] U.Y. Choi, J.J. Lee, A. Park, W. Zhu, H.-R. Lee, Y.J. Choi, et al., Oncogenic human herpesvirus hijacks proline metabolism for tumorigenesis, Proc. Natl. Acad. Sci. Unit. States Am. 117 (14) (2020 Apr 7) 8083–8093.